This study focuses on Polycythemia Vera (PV), a rare blood disorder where the body produces too many red blood cells. The research compares three different treatments: ruxolitinib (also known as Jakavi), hydroxycarbamide, and peginterferon alfa-2a (also known as Pegasys) as initial treatments for high-risk Polycythemia Vera patients.
The purpose of the study is to determine which treatment is most effective at preventing serious complications in patients with high-risk Polycythemia Vera. The study will monitor patients for major blood clots, severe bleeding, disease progression to other blood disorders such as Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Post-PV Myelofibrosis, and overall survival.
Patients will be randomly assigned to receive either ruxolitinib tablets taken by mouth, or one of two comparison treatments: hydroxycarbamide capsules taken by mouth, or peginterferon alfa-2a given as an injection under the skin. The treatment and monitoring period will continue for up to 96 months, during which patients will have regular check-ups to assess their response to treatment and monitor for any side effects.
France 
